1.67
-0.01(-0.60%)
Currency In USD
| Previous Close | 1.68 |
| Open | 1.68 |
| Day High | 1.73 |
| Day Low | 1.65 |
| 52-Week High | 2.27 |
| 52-Week Low | 0.77 |
| Volume | 1.77M |
| Average Volume | 2.6M |
| Market Cap | 175.85M |
| PE | -5.57 |
| EPS | -0.3 |
| Moving Average 50 Days | 1.79 |
| Moving Average 200 Days | 1.44 |
| Change | -0.01 |
If you invested $1000 in SELLAS Life Sciences Group, Inc. (SLS) 10 years ago, it would be worth $0.03 as of September 16, 2025 at a share price of $1.67. Whereas If you bought $1000 worth of SELLAS Life Sciences Group, Inc. (SLS) shares 5 years ago, it would be worth $759.09 as of September 16, 2025 at a share price of $1.67.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
SELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $23.6 Million in Gross Proceeds
GlobeNewswire Inc.
Sep 11, 2025 12:30 PM GMT
NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indic
SELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 REGAL Trial of GPS in AML Without Modification
GlobeNewswire Inc.
Aug 07, 2025 12:30 PM GMT
- Final Analysis Anticipated by Year-End Upon Occurrence of 80 Events - NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical c
SELLAS Meets All Primary Endpoints in Phase 2 Trial of SLS009 in r/r AML and Receives FDA Guidance to Advance into First-Line Therapy Study
GlobeNewswire Inc.
Jul 15, 2025 11:45 AM GMT
The Trial Exceeded Target Overall Response Rate (ORR) of 20%, with 44% Response Rate Among Patients with Acute Myeloid Leukemia-Myelodysplasia-Related Changes (AML MR) Treated at Optimal Dose of 30 mg Twice a Week (BIW) and 50% in AML MR with Myelomo